Document is current
Any future updates will be listed below
-
Authors
Yang, Shengtao https://orcid.org/0000-0002-9997-5427
Datta, Dibyadeep
Elizabeth Woo,
Duque, Alvaro https://orcid.org/0000-0002-5086-5438
Morozov, Yury M.
Arellano, Jon
Slusher, Barbara S.
Wang, Min
Arnsten, Amy F. T. https://orcid.org/0000-0002-3420-1308
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG061190, AG068130, AG068130)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH113257, MH113257)
Alzheimer's Association (AARF-17-533294, AARF-17-533294)
American Federation for Aging Research
Alzheimer's Association
American Federation for Aging Research (no number)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Aging
- License Information
-
More Information
Article History
Received: 6 March 2022
Accepted: 27 May 2022
First Online: 22 June 2022
Competing interests
: Yale University and AFTA receive royalties from Shire/Takeda from the USA sales of Intuniv (extended release guanfacine). They do not receive royalties from international sales, nor from sales of generic Intuniv. Johns Hopkins University and BSS have patents US9737552B2, US20180338910A1, WO2018094334A1 and WO2016022827A1 related to GCPII inhibitors.
